Ascentage, Takeda Pharmaceutical Company
The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some safety setbacks and years of generic competition, Takeda is calling it quits ...
Riyadh, The Kingdom of Saudi Arabia: Takeda, the global biopharmaceutical company, is pleased to announce a new strategic ...
Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...
Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...
Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...
More than 250 people — a mix of construction crew members, community and business leaders, and Takeda employees — braved ...
Gaming Legends on MSN4d
Mortal Kombat X #31 Takeda VS. The Fatal Eight (Read & Review)SUBSCRIBE! Never Miss A Video: <a href=" to read the issue for yourself with all the text? Click right here to buy the issue ...
LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...
The INTERCEPT study is being funded to the tune of €38 million (nearly $40 million) over the next five years and is described ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback